Prestige Consumer Healthcare Inc. $PBH Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 70.0% during the first quarter, Holdings Channel reports. The fund owned 6,993 shares of the company’s stock after selling 16,299 shares during the quarter. Lazard Asset Management LLC’s holdings in Prestige Consumer Healthcare were worth $414,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PBH. AQR Capital Management LLC boosted its holdings in Prestige Consumer Healthcare by 11.9% in the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after purchasing an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after purchasing an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares in the last quarter. Jane Street Group LLC raised its position in shares of Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after purchasing an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $54.92 on Friday. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $71.07. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 2.25. The stock has a fifty day moving average price of $48.82 and a 200 day moving average price of $56.06. The company has a market cap of $2.60 billion, a P/E ratio of 15.38, a PEG ratio of 1.69 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million for the quarter, compared to analysts’ expectations of $250.34 million. During the same period last year, the business posted $0.90 earnings per share. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.6 earnings per share for the current year.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment.
• Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results
• Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031.
• Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target
• Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability.
• Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions.

Analyst Ratings Changes

A number of research firms have recently weighed in on PBH. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Finally, Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).